DailyIQ
|
Sector:Financial ServicesAll sectors
Last updated 22 minutes ago

AJG·Arthur J. Gallagher & Co.

$.
-. (-.%)
After Hours
High
$255.50
Open
$254.90
Market Cap
64.95B
52W High
$316.71
Low
$250.94
P. Close
$253.00
P/E
40.30
52W Low
$190.75
Fwd P/E
17.02
DailyIQ Est.
$289.09
Technical Score (1D)
86
BUY
News Sentiment
68
BULLISH
The most recent development is AJG’s acquisition of Med James, which adds a new MGA and wholesale brokerage arm that expands its health‑insurance distribution network, especially in the Midwest. This expansion should increase AJG’s cross‑selling opportunities and broaden its product mix, potentially boosting revenue in the near term. Traders should monitor the integration timeline and any regulatory approvals, as delays could dampen the expected upside. The acquisition also brings additional distribution channels that could accelerate the realization of synergies, a key factor for value creation. Meanwhile, AJG has announced that its Q2 2026 earnings will be released after market close on July 30, setting a clear date for upcoming earnings analysis. The earnings release timing may influence intraday volatility and provide a benchmark against which the acquisition’s impact will be assessed. In addition, Wells Fargo upgraded AJG to Overweight and raised its price target to $299, while Cantor Fitzgerald kept a Neutral rating but lifted its target to $300, signaling a generally bullish outlook. These rating changes suggest that analysts expect the acquisition to support growth, but they remain cautious about short‑term risks. Therefore, the next key watch items are the integration progress of Med James, the regulatory approval status, the Q2 earnings results, and any subsequent analyst commentary that may adjust the growth narrative.
Earnings Summary
Arthur J. Gallagher & Co. (AJG) is a global insurance brokerage and risk‑management firm that serves commercial, industrial, and public clients through its Brokerage and Risk Management segments, offering placement, claims settlement, and consulting services. Operating in the financial services sector, AJG competes with other insurance brokers and has built a broad network of brokers and consultants since 1927. In the most recent quarters, AJG posted a Q4 2024 EPS of $2.13 versus an estimate of $2.03 and revenue of $2.68 billion, followed by a Q1 2025 EPS of $3.67 versus $3.58 and revenue of $3.68 billion; the next two quarters saw EPS of $2.33 and $2.32 with revenues of $3.17 billion and $3.33 billion, respectively, before a Q4 2025 EPS of $2.38 versus a $4.45 estimate and revenue of $3.59 billion, and a Q1 2026 EPS of $4.47 versus $4.47 and revenue of $4.72 billion. Compared with the prior two quarters, the last two quarters show a sharp EPS rebound from $2.32 to $4.47 and a revenue rise from $3.33 billion to $4.72 billion, while the company has alternated between beating and missing estimates—three beats (Q4 2024, Q1 2025, Q1 2026) and three misses (Q2 2025, Q3 2025, Q4 2025). Historically, AJG’s revenue has trended upward year over year, with a notable 45 % jump from Q4 2024 to Q1 2025, a dip in Q2 2025, and a strong 31 % increase into Q1 2026, whereas EPS volatility has been pronounced, reflecting fluctuating underwriting and cost dynamics. Recent news highlights AJG’s acquisition of Med James, WMB, and Wilson M. Beck, expanding its MGA and wholesale brokerage capabilities in the Midwest and Canada, and has prompted rating upgrades to overweight with higher price targets; these deals are expected to broaden product mix and cross‑sell opportunities, though integration timelines and regulatory approvals remain key risks. Forward‑looking watch points include monitoring the progress of the Med James and WMB integrations, any regulatory clearance updates, the Q2 2026 earnings release scheduled for July 30, and how the company’s underwriting performance and capital adequacy metrics evolve, as these factors will shape the next earnings narrative.

EPS

EstBeatMiss
$2.00$2.70$3.40$4.10$4.79Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.82 - -
Q1'26$4.47$4.47-0.0%
Q4'25$4.45$2.38-46.5%
Q3'25$2.54$2.32-8.5%
Q2'25$2.34$2.33-0.6%
Q1'25$3.58$3.67+2.5%

Revenue

EstBeatMiss
$2.9B$3.5B$4.0B$4.5B$5.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.0B - -
Q1'26$4.8B$4.7B-1.4%
Q4'25$4.8B$3.6B-25.8%
Q3'25 - $3.3B -
Q2'25 - $3.2B -
Q1'25 - $3.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AJG Stock Snapshot

AJG is currently trading at $253.09, giving Arthur J. Gallagher & Co. a market cap of 64.95B and a P/E ratio of 40.3. Today's range spans $250.94–$255.50, with shares opening at $254.90 and moving up $0.09 (0.0%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 68/100.

Over the past year AJG has traded between $190.75 and $316.71 - the current price is +32.7% off the 52-week low and -20.1% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $273.33 (range $225.00–$388.00), implying upside of +8.0%.

Arthur J. Gallagher & Co. (AJG) sits at $253.09 (in the middle of its 52-week range within $190.75–$316.71), scoring 86/100 (BUY) with bullish sentiment at 68/100. At 64.95B in Financial Services market cap (P/E: 40.3), this large-cap is right in the zone where buy-side analysts get excited and allocation committees approve new position additions. A bullish technical phase with sentiment confirmation is the green light most of them are looking for.

Earnings revision cycles in large-cap Financial Services names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $253.09 (in the middle of its 52-week range), AJG's position within the $190.75–$316.71 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.